scholarly journals 5-Methyl-N-(8-(5,6,7,8-tetrahydroacridin-9-ylamino)octyl)-5H-indolo[2,3-b]quinolin-11-amine: a highly potent human cholinesterase inhibitor

MedChemComm ◽  
2017 ◽  
Vol 8 (6) ◽  
pp. 1307-1317 ◽  
Author(s):  
Li Wang ◽  
Ignacio Moraleda ◽  
Isabel Iriepa ◽  
Alejandro Romero ◽  
Francisco López-Muñoz ◽  
...  
Keyword(s):  
Cholinesterase Inhibitor ◽  
Human Cholinesterase

5-Methyl-N-(8-(5,6,7,8-tetrahydroacridin-9-ylamino)octyl)-5H-indolo[2,3-b]quinolin-11-amine is a very potent human ChE inhibitor [IC50(hAChE) = 0.95 ± 0.04 nM].

scholarly journals Cerebrospinal Fluid Hypocretin and Nightmares in Dementia Syndromes

2021 ◽  
pp. 19-25
Author(s):  
Lynn Marie Trotti ◽  
Donald L. Bliwise ◽  
Glenda L. Keating ◽  
David B. Rye ◽  
William T. Hu
Keyword(s):  
Cerebrospinal Fluid ◽  
Alzheimer Disease ◽  
Cholinesterase Inhibitor ◽  
Dementia With Lewy Bodies ◽  
Lewy Bodies ◽  
Cognitively Normal ◽  
Dementia Patients ◽  
Sleep Questionnaires ◽  
Sleep Alterations ◽  
Normal Controls

Background/Aims: Hypocretin promotes wakefulness and modulates REM sleep. Alterations in the hypocretin system are increasingly implicated in dementia. We evaluated relationships among hypocretin, dementia biomarkers, and sleep symptoms in elderly participants, most of whom had dementia. Methods: One-hundred twenty-six adults (mean age 66.2 ± 8.4 years) were recruited from the Emory Cognitive Clinic. Diagnoses were Alzheimer disease (AD; n = 60), frontotemporal dementia (FTD; n = 21), and dementia with Lewy bodies (DLB; n = 20). We also included cognitively normal controls (n = 25). Participants and/or caregivers completed sleep questionnaires and lumbar puncture was performed for cerebrospinal fluid (CSF) assessments. Results: Except for sleepiness (worst in DLB) and nocturia (worse in DLB and FTD) sleep symptoms did not differ by diagnosis. CSF hypocretin concentrations were available for 87 participants and normal in 70, intermediate in 16, and low in 1. Hypocretin levels did not differ by diagnosis. Hypocretin levels correlated with CSF total τ levels only in men (r = 0.34; p = 0.02). Lower hypocretin levels were related to frequency of nightmares (203.9 ± 29.8 pg/mL in those with frequent nightmares vs. 240.4 ± 46.1 pg/mL in those without; p = 0.05) and vivid dreams (209.1 ± 28.3 vs. 239.5 ± 47.8 pg/mL; p = 0.014). Cholinesterase inhibitor use was not associated with nightmares or vivid dreaming. Conclusion: Hypocretin levels did not distinguish between dementia syndromes. Disturbing dreams in dementia patients may be related to lower hypocretin concentrations in CSF.

scholarly journals Clinanthus microstephium , an Amaryllidaceae Species with Cholinesterase Inhibitor Alkaloids: Structure−Activity Analysis of Haemanthamine Skeleton Derivatives

2019 ◽  
Vol 16 (5) ◽  
pp. e1800662
Author(s):  
Tonino G. Adessi ◽  
José L. Borioni ◽  
Natalia B. Pigni ◽  
Jaume Bastida ◽  
Valeria Cavallaro ◽  
...  
Keyword(s):  
Cholinesterase Inhibitor ◽  
Activity Analysis ◽  
Structure Activity

A case with cholinesterase inhibitor responsive asymmetric posterior cortical atrophy

2005 ◽  
Vol 108 (1) ◽  
pp. 97-101 ◽  
Author(s):  
Eunhee Kim ◽  
Yunsoo Lee ◽  
Jongkeol Lee ◽  
Seol-Heui Han
Keyword(s):  
Cholinesterase Inhibitor ◽  
Cortical Atrophy ◽  
Posterior Cortical Atrophy

Cholinesterase inhibitor treatment in patients with delirium – Authors' reply

The Lancet ◽  
2011 ◽  
Vol 377 (9769) ◽  
pp. 901
Author(s):  
Maarten MJ van Eijk ◽  
Willem A van Gool ◽  
Arjen JC Slooter
Keyword(s):  
Cholinesterase Inhibitor ◽  
Inhibitor Treatment
Sign in / Sign up

Export Citation Format

Share Document